Long-term effectiveness of irreversible electroporation in a murine model of colorectal liver metastasis.
Irreversible electroporation (IRE) has recently gained in popularity as an ablative technique, however little is known about its oncological long-term outcomes. To determine the long-time survival of animals treated with a high dose of IRE and which histological changes it induces in tumoral tissue, IRE ablation was performed in forty-six athymic-nude mice with KM12C tumors implanted in the liver by applying electric current with different voltages (2000 V/cm, 1000 V/cm). The tumors were allowed to continue to grow until the animals reached the end-point criteria. Histology was harvested and the extent of tumor necrosis was semi-quantitatively assessed. IRE treatment with the 2000 V/cm protocol significantly prolonged median mouse survival from 74.3 ± 6.9 days in the sham group to 112.5 ± 15.2 days in the 2000 V/cm group. No differences were observed between the mean survival of the 1000 V/cm and the sham group (83.2 ± 16.4 days, p = 0.62). Histology revealed 63.05% ± 23.12 of tumor necrosis in animals of the 2000 V/cm group as compared to 17.50% ± 2.50 in the 1000 V/cm group and 25.6% ± 22.1 in the Sham group (p = 0.001). IRE prolonged the survival of animals treated with the highest electric field (2000 V/cm). The animals in this group showed significantly higher rate of tumoral necrosis.
Department of Surgery, Hospital del Mar, Passeig Marítim 25-29, 08003, Barcelona, Spain.|Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain.
P
P
Sánchez-Velázquez
Department of Information and Communication Technologies, Universitat Pompeu Fabra, Carrer Roc Boronat 138, 08018, Barcelona, Spain.
Q
Q
Castellví
Translational Research Laboratory, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Av. de la Granvia de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
A
A
Villanueva
Departament of Pathology, Hospital del Mar, Passeig Marítim 25-29, 08003, Barcelona, Spain.|Universitat Autònoma de Barcelona, Plaça Cívica, s/n, 08193 Bellaterra, Barcelona, Spain.
M
M
Iglesias
Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain.
R
R
Quesada
Department of Surgery, Hospital del Mar, Passeig Marítim 25-29, 08003, Barcelona, Spain.
C
C
Pañella
Department of Surgery, Hospital del Mar, Passeig Marítim 25-29, 08003, Barcelona, Spain.
M
M
Cáceres
Department of Surgery, Hospital del Mar, Passeig Marítim 25-29, 08003, Barcelona, Spain.
D
D
Dorcaratto
Department of Animal Medicine and Surgery, Faculty of Veterinary Medicine, Autonomous University of Barcelona (U.A.B.), Plaza Cívica, s/n, 08193 Bellaterra, Barcelona, Spain.
A
A
Andaluz
Department of Animal Medicine and Surgery, Faculty of Veterinary Medicine, Autonomous University of Barcelona (U.A.B.), Plaza Cívica, s/n, 08193 Bellaterra, Barcelona, Spain.
X
X
Moll
Department of Electric Engineering and Communications, University of Zaragoza, Pedro Cerbuna, 12, 50018 Zaragoza, Spain.
J M
JM
Burdío
Department of Surgery, Hospital del Mar, Passeig Marítim 25-29, 08003, Barcelona, Spain.
L
L
Grande
Department of Information and Communication Technologies, Universitat Pompeu Fabra, Carrer Roc Boronat 138, 08018, Barcelona, Spain.|Serra Húnter Fellow, Universitat Pompeu Fabra, Carrer Roc Boronat 138, 08018, Barcelona, Spain.
A
A
Ivorra
Department of Surgery, Hospital del Mar, Passeig Marítim 25-29, 08003, Barcelona, Spain.|Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain.
F
F
Burdío
D055011:Ablation Techniques; D000818:Animals; D001706:Biopsy; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000473:pathology*; D004195:Disease Models, Animal; D018274:Electroporation / Q000379:methods; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D008297:Male; D051379:Mice; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays